UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

The New England journal of medicine, 2017-08, Vol.377 (8), p.723-732

2017

Link zum Volltext

Verfügbarkeit prüfen

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1142-1149

2015

Link zum Volltext

Verfügbarkeit prüfen

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Diabetologia, 2020-04, Vol.63 (4), p.698-710

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Expert opinion on drug metabolism & toxicology, 2015, Vol.11 (8), p.1193-1201

2015

Link zum Volltext

Verfügbarkeit prüfen

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1032-1039

2017

Link zum Volltext

Verfügbarkeit prüfen

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.386-394

2015

Link zum Volltext

Verfügbarkeit prüfen

Optimal prandial timing of bolus insulin in diabetes management: a review

Diabetic medicine, 2018-03, Vol.35 (3), p.306-316

2018

Link zum Volltext

Verfügbarkeit prüfen

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1024-1031

2017

Link zum Volltext

Verfügbarkeit prüfen

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Diabetic medicine, 2016-04, Vol.33 (4), p.471-477

2016

Link zum Volltext

Verfügbarkeit prüfen

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Cochrane database of systematic reviews, 2020-11, Vol.11 (11), p.CD005613

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-02, Vol.327 (6), p.534

2022

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-11, Vol.330 (17), p.1631

2023

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.159-168

2016

Link zum Volltext

Verfügbarkeit prüfen

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2384-2393

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2413-2421

2019

Link zum Volltext

Verfügbarkeit prüfen

The past, present, and future of basal insulins

Diabetes/metabolism research and reviews, 2016-09, Vol.32 (6), p.478-496

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Diabetes care, 2015-12, Vol.38 (12), p.2226-2233

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Diabetes care, 2018-05, Vol.41 (5), p.1009-1016

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-07, Vol.318 (1), p.45

2017

Link zum Volltext

Verfügbarkeit prüfen

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

The New England journal of medicine, 2020-11, Vol.383 (22), p.2107-2116

2020

Link zum Volltext

Verfügbarkeit prüfen

Exercise and insulin glargine administration in mothers with diabetes during pregnancy ameliorate function of testis in offspring: Consequences on apelin-13 and its receptor

Life sciences (1973), 2024-04, Vol.342, p.122517-122517, Article 122517

2024

Link zum Volltext

Verfügbarkeit prüfen

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.366-374

2016

Link zum Volltext

Verfügbarkeit prüfen

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)

Diabetes, obesity & metabolism, 2015-08, Vol.17 (8), p.734-741

2015

Link zum Volltext

Verfügbarkeit prüfen

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Diabetes care, 2016-11, Vol.39 (11), p.2026-2035

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-07, Vol.318 (1), p.33

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 3.156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.330)
Mit Volltextzugriff
(2.523)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Insulin Glargine
(2.422)
Science & Technology
(2.262)
Life Sciences & Biomedicine
(2.225)
Humans
(2.087)
Endocrinology & Metabolism
(1.400)
Insulin
(1.398)
Diabetes Mellitus, Type 2 - Drug Therapy
(1.260)
Diabetes
(1.211)
Female
(1.168)
Male
(1.161)
Hypoglycemic Agents - Therapeutic Use
(1.019)
Middle Aged
(918)
Type 2 Diabetes
(916)
Insulin - Analogs & Derivatives
(901)
Insulin, Long-Acting
(817)
Hypoglycemic Agents - Administration & Dosage
(772)
Hypoglycemia
(687)
Insulin - Therapeutic Use
(685)
Adult
(673)
Aged
(638)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Diabetes, Obesity & Metabolism
(264)
Diabetes Care
(199)
Diabetes Therapy
(111)
Pr Newswire
(87)
Diabetes Technology & Therapeutics
(76)
Diabetes Research And Clinical Practice
(74)
Diabetic Medicine
(71)
Diabetologia
(58)
M2 Presswire
(52)
Current Medical Research And Opinion
(48)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(9)
... seit 90 Tagen
(43)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Optimal prandial timing of bolus insulin in diabetes management: a review

Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100

The past, present, and future of basal insulins

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment

Exercise and insulin glargine administration in mothers with diabetes during pregnancy ameliorate function of testis in offspring: Consequences on apelin-13 and its receptor

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

Suchergebnisse filtern